Should I buy or sell DermTech stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DMTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DMTK, but not buy additional shares or sell existing shares. View DMTK analyst ratings or view top-rated stocks .

What is DermTech's stock price target for 2024?

3 Wall Street research analysts have issued 1-year target prices for DermTech's stock. Their DMTK share price targets range from $0.63 to $5.00. On average, they predict the company's stock price to reach $2.38 in the next twelve months. This suggests a possible upside of 269.0% from the stock's current price. View analysts price targets for DMTK or view top-rated stocks among Wall Street analysts .

How have DMTK shares performed in 2024?

DermTech's stock was trading at $1.75 on January 1st, 2024. Since then, DMTK shares have decreased by 63.2% and is now trading at $0.6440. View the best growth stocks for 2024 here .

When is DermTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our DMTK earnings forecast .

How were DermTech's earnings last quarter?

DermTech, Inc. (NASDAQ:DMTK) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.02. The firm had revenue of $3.92 million for the quarter, compared to analysts' expectations of $4.05 million. DermTech had a negative trailing twelve-month return on equity of 123.96% and a negative net margin of 659.57%.

What other stocks do shareholders of DermTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE) , CrowdStrike (CRWD) , DocuSign (DOCU) , ONEOK (OKE) , Intel (INTC) , U.S. Xpress Enterprises (USX) , Valero Energy (VLO) , Hello Group (MOMO) , AVEO Pharmaceuticals (AVEO) and Camping World (CWH) .

How do I buy shares of DermTech?

Shares of DMTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:DMTK

DermTech (DMTK) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free DMTK Stock Alerts

$0.64

+0.05 (+8.42%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.60
▼
$0.69
50-Day Range: $0.59
▼
$1.36
52-Week Range: $0.59
▼
$4.36

Volume: 677,550 shs
Average Volume: 323,111 shs
Market Capitalization: $22.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.38

Get DermTech alerts:

DermTech MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 269.0% Upside
$2.38 Price Target
Short Interest: Bearish
10.31% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.07
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.94) to ($1.53) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.82 out of 5 stars

Medical Sector

826th out of 911 stocks

Medical Laboratories Industry

19th out of 20 stocks

3.0

Analyst's Opinion

Consensus Rating
DermTech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
DermTech has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
10.31% of the float of DermTech has been sold short.
Short Interest Ratio / Days to Cover
DermTech has a short interest ratio ("days to cover") of 9.4.
Change versus previous month
Short interest in DermTech has recently increased by 0.64%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
DermTech does not currently pay a dividend.
Dividend Growth
DermTech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DMTK.

1.6

News and Social Media Coverage

News Sentiment
DermTech has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for DermTech this week, compared to 2 articles on an average week.
MarketBeat Follows
4 people have added DermTech to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, DermTech insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.10% of the stock of DermTech is held by insiders.
Percentage Held by Institutions
Only 20.45% of the stock of DermTech is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for DermTech are expected to grow in the coming year, from ($1.94) to ($1.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of DermTech is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of DermTech is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
DermTech has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About DermTech Stock (NASDAQ:DMTK)

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

DMTK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DMTK Stock News Headlines

April 19, 2024 | msn.com

BTIG Downgrades DermTech (DMTK)

April 19, 2024 | markets.businessinsider.com

What Analysts Are Saying About DermTech Stock

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 18, 2024 | marketwatch.com

DermTech to Slash 56% of Workforce, Explore Options

April 18, 2024 | msn.com

DermTech exploring strategic alternatives, cutting 56% of staff

April 18, 2024 | businesswire.com

DermTech to Explore Strategic Alternatives and Implement Restructuring Plan

April 17, 2024 | finance.yahoo.com

DermTech, Inc. (DMTK)

April 17, 2024 | americanbankingnews.com

DermTech (NASDAQ:DMTK) Trading Down 0.9%

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 8, 2024 | businesswire.com

DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology

March 7, 2024 | investing.com

Stephens cuts DermTech stock target to $1.50, keeps Equal Weight rating

March 2, 2024 | finance.yahoo.com

DermTech, Inc. (NASDAQ:DMTK) Q4 2023 Earnings Call Transcript

February 29, 2024 | benzinga.com

Recap: DermTech Q4 Earnings

February 29, 2024 | businesswire.com

DermTech Reports Fourth-Quarter 2023 Financial Results

February 28, 2024 | msn.com

DermTech Q4 2023 Earnings Preview

February 13, 2024 | finance.yahoo.com

DermTech Announces Release Date for Fourth-quarter 2023 Financial Results

February 1, 2024 | markets.businessinsider.com

DermTech International Registered Shs

January 31, 2024 | marketwatch.com

DermTech to Cut Workforce by 15%, Six Months After Round of Layoffs

January 31, 2024 | finance.yahoo.com

DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations

January 18, 2024 | msn.com

DermTech study finds melanoma test effective for all skin types

January 18, 2024 | finance.yahoo.com

DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types

January 16, 2024 | finance.yahoo.com

DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay

January 8, 2024 | marketwatch.com

DermTech Shares Rise 14% After Positive Results in Melanoma Test Study

January 8, 2024 | seekingalpha.com

DermTech stock rallies 18% on positive study for melanoma test

January 8, 2024 | finance.yahoo.com

DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)

January 3, 2024 | benzinga.com

DermTech Stock (NASDAQ:DMTK) Dividends: History, Yield and Dates

December 29, 2023 | businesswire.com

DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

See More Headlines

Receive DMTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:DMTK
CUSIP: N/A
CIK: 1651944
Web: www.dermtech.com
Phone: (858) 450-4222
Fax: N/A
Employees: 206
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.38
High Stock Price Target: $5.00
Low Stock Price Target: $0.63
Potential Upside/Downside: +269.0%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-100,890,000.00
Net Margins: -659.57%
Pretax Margin: -659.57%
Return on Equity: -123.96%
Return on Assets: -67.94%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.59
Quick Ratio: 4.52

Sales & Book Value

Annual Sales: $15.30 million
Price / Sales: 1.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.67 per share
Price / Book: 0.39

Miscellaneous

Outstanding Shares: 34,620,000
Free Float: 32,857,000
Market Cap: $22.30 million
Optionable: Optionable
Beta: 2.52

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Kevin Sun M.B.A. (Age 46)
CFO, Treasurer & Secretary
Comp: $461.92k
Mr. Ray Akhavan Esq. (Age 55)
J.D., General Counsel
Comp: $413.06k
Mr. Bret Christensen (Age 53)
President, CEO & Director
Mr. William W. Zondler
Chief Information Officer
Mr. Steve E. Kunszabo
Senior Director of Investor Relations
Ms. Jennifer Eilemberg
Chief Compliance Officer
Dr. Burkhard Jansen M.D. (Age 58)
Chief Medical Affairs Officer
Comp: $419.8k
Dr. Loren Clarke M.D.
Chief Medical Officer
Dr. Steven Stone Ph.D.
Senior Vice President of Research & Development
Mr. Mark Aguillard
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DMTK Stock Analysis - Frequently Asked Questions

Should I buy or sell DermTech stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DMTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DMTK, but not buy additional shares or sell existing shares.
View DMTK analyst ratings or view top-rated stocks.
What is DermTech's stock price target for 2024?: 3 Wall Street research analysts have issued 1-year target prices for DermTech's stock. Their DMTK share price targets range from $0.63 to $5.00. On average, they predict the company's stock price to reach $2.38 in the next twelve months. This suggests a possible upside of 269.0% from the stock's current price.
View analysts price targets for DMTK or view top-rated stocks among Wall Street analysts.
How have DMTK shares performed in 2024?: DermTech's stock was trading at $1.75 on January 1st, 2024. Since then, DMTK shares have decreased by 63.2% and is now trading at $0.6440.
View the best growth stocks for 2024 here.
When is DermTech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our DMTK earnings forecast.

How were DermTech's earnings last quarter?: DermTech, Inc. (NASDAQ:DMTK) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.02. The firm had revenue of $3.92 million for the quarter, compared to analysts' expectations of $4.05 million. DermTech had a negative trailing twelve-month return on equity of 123.96% and a negative net margin of 659.57%.
What other stocks do shareholders of DermTech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), DocuSign (DOCU), ONEOK (OKE), Intel (INTC), U.S. Xpress Enterprises (USX), Valero Energy (VLO), Hello Group (MOMO), AVEO Pharmaceuticals (AVEO) and Camping World (CWH).
How do I buy shares of DermTech?: Shares of DMTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DMTK) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial